Introduction: Hereditary hemorrhagic telangiectasia as a rare disease

Erica Daina, Francesco D'Ovidio, Carlo Sabbà

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

A disease is considered rare in the United States when it affects one individual per 1, 250 and one individual per 2,000 in Europe. Most rare diseases (RD) are of genetic origin; their rarity involves a difficult and/or late diagnosis. The greatest barrier to prevention, diagnosis and treatment of RD is inadequate knowledge. Hereditary haemorrhagic telangiectasia (HHT) is a "rare" genetic disorder that is becoming more commonly recognised. Recent evidence indicates that it is more frequent (1-2/10, 000) than previously estimated. We suppose that the frequent misdiagnosis and the different genetic ponetrance have led to an underestimation of real prevalence. In fiact, progress in scientific knowledge and improvement in diagnostic and therapeutic technologies has unmasked conditions which were not fully known previously, determining a fictitious decrease in disease frequency.

Original languageEnglish
Pages (from-to)1171-1172
Number of pages2
JournalCurrent Pharmaceutical Design
Volume12
Issue number10
DOIs
Publication statusPublished - Apr 2006

Fingerprint

Hereditary Hemorrhagic Telangiectasia
Rare Diseases
Inborn Genetic Diseases
Delayed Diagnosis
Diagnostic Errors
Technology
Therapeutics

Keywords

  • Hereditary haemorrhagic telangiectasia
  • Rare disease

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Introduction : Hereditary hemorrhagic telangiectasia as a rare disease. / Daina, Erica; D'Ovidio, Francesco; Sabbà, Carlo.

In: Current Pharmaceutical Design, Vol. 12, No. 10, 04.2006, p. 1171-1172.

Research output: Contribution to journalArticle

Daina, Erica ; D'Ovidio, Francesco ; Sabbà, Carlo. / Introduction : Hereditary hemorrhagic telangiectasia as a rare disease. In: Current Pharmaceutical Design. 2006 ; Vol. 12, No. 10. pp. 1171-1172.
@article{3ea04bfe635f42b8acbfa51d6583c037,
title = "Introduction: Hereditary hemorrhagic telangiectasia as a rare disease",
abstract = "A disease is considered rare in the United States when it affects one individual per 1, 250 and one individual per 2,000 in Europe. Most rare diseases (RD) are of genetic origin; their rarity involves a difficult and/or late diagnosis. The greatest barrier to prevention, diagnosis and treatment of RD is inadequate knowledge. Hereditary haemorrhagic telangiectasia (HHT) is a {"}rare{"} genetic disorder that is becoming more commonly recognised. Recent evidence indicates that it is more frequent (1-2/10, 000) than previously estimated. We suppose that the frequent misdiagnosis and the different genetic ponetrance have led to an underestimation of real prevalence. In fiact, progress in scientific knowledge and improvement in diagnostic and therapeutic technologies has unmasked conditions which were not fully known previously, determining a fictitious decrease in disease frequency.",
keywords = "Hereditary haemorrhagic telangiectasia, Rare disease",
author = "Erica Daina and Francesco D'Ovidio and Carlo Sabb{\`a}",
year = "2006",
month = "4",
doi = "10.2174/138161206776361264",
language = "English",
volume = "12",
pages = "1171--1172",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "10",

}

TY - JOUR

T1 - Introduction

T2 - Hereditary hemorrhagic telangiectasia as a rare disease

AU - Daina, Erica

AU - D'Ovidio, Francesco

AU - Sabbà, Carlo

PY - 2006/4

Y1 - 2006/4

N2 - A disease is considered rare in the United States when it affects one individual per 1, 250 and one individual per 2,000 in Europe. Most rare diseases (RD) are of genetic origin; their rarity involves a difficult and/or late diagnosis. The greatest barrier to prevention, diagnosis and treatment of RD is inadequate knowledge. Hereditary haemorrhagic telangiectasia (HHT) is a "rare" genetic disorder that is becoming more commonly recognised. Recent evidence indicates that it is more frequent (1-2/10, 000) than previously estimated. We suppose that the frequent misdiagnosis and the different genetic ponetrance have led to an underestimation of real prevalence. In fiact, progress in scientific knowledge and improvement in diagnostic and therapeutic technologies has unmasked conditions which were not fully known previously, determining a fictitious decrease in disease frequency.

AB - A disease is considered rare in the United States when it affects one individual per 1, 250 and one individual per 2,000 in Europe. Most rare diseases (RD) are of genetic origin; their rarity involves a difficult and/or late diagnosis. The greatest barrier to prevention, diagnosis and treatment of RD is inadequate knowledge. Hereditary haemorrhagic telangiectasia (HHT) is a "rare" genetic disorder that is becoming more commonly recognised. Recent evidence indicates that it is more frequent (1-2/10, 000) than previously estimated. We suppose that the frequent misdiagnosis and the different genetic ponetrance have led to an underestimation of real prevalence. In fiact, progress in scientific knowledge and improvement in diagnostic and therapeutic technologies has unmasked conditions which were not fully known previously, determining a fictitious decrease in disease frequency.

KW - Hereditary haemorrhagic telangiectasia

KW - Rare disease

UR - http://www.scopus.com/inward/record.url?scp=33744978818&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33744978818&partnerID=8YFLogxK

U2 - 10.2174/138161206776361264

DO - 10.2174/138161206776361264

M3 - Article

C2 - 16611098

AN - SCOPUS:33744978818

VL - 12

SP - 1171

EP - 1172

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 10

ER -